|
|
Prof Matti Aapro (University of Geneva) Prof Joachim Fandrey (Essen University, Germany) Prof Dirk Schrijvers (Middelheim Hospital, Antwerp) and Prof Anders Österborg (Karolinska Institutet, Stockholm) discuss the best way to manage anaemia in cancer patients, at the Anaemia Management Update meeting, 7.11.10, Amsterdam. They also discuss highlights from the meeting and cover topics such as frequency of transfusion, shelf life of blood, erythropoiesis-stimulating agents (ESAs), erythropoietin receptors, government regulation, erythropoietic agents, Darbepoetin alfa, Myelodysplastic syndrome and treating elderly patients.This content has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company)
|
|
Video Length: 0
Date Found: January 27, 2011
Date Produced:
|
|
 www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
 www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
 www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
 www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
 www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|